Alnylam Pharmaceuticals ALNY

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$3.61 (-1.45%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Alnylam Pharmaceuticals (ALNY)
    Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $244.52

    • Market Cap

      $31.65 Billion

    • Price-Earnings Ratio

      -112.17

    • Total Outstanding Shares

      129.46 Million Shares

    • Total Employees

      2,230

    • Dividend

      No dividend

    • IPO Date

      May 28, 2004

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      675 west kendall street, Cambridge, MA, 02142

    • Homepage

      https://www.alnylam.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Financing Activities$294.16 Million
    Net Cash Flow From Investing Activities$-116.84 Million
    Net Cash Flow, Continuing$169.01 Million
    Net Cash Flow From Investing Activities, Continuing$-116.84 Million
    Net Cash Flow From Operating Activities$-8.31 Million
    Net Cash Flow From Financing Activities, Continuing$294.16 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Income/Loss From Continuing Operations After Tax$-278.16 Million
    Gross Profit$1.94 Billion
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Basic Earnings Per Share$-2.18
    Operating Expenses$2.12 Billion

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Comprehensive Income/Loss Attributable To Parent$-11.14 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-289.30 Million
    Comprehensive Income/Loss$-289.30 Million
    Other Comprehensive Income/Loss$-11.14 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Wages$214.40 Million
    Accounts Payable$88.42 Million
    Other Non-current Assets$441.91 Million
    Inventory$78.51 Million
    Equity Attributable To Noncontrolling Interest$0
    Liabilities$4.17 Billion

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ALNY from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.